Tyra Biosciences, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation precision medicines targeting large opportunities in fibroblast growth factor receptor (FGFR) biology. Founded in 2018 and headquartered in Carlsbad, California, Tyra leverages its proprietary SNÅP platform for precision drug discovery aimed at overcoming acquired resistance to current cancer therapies. The company’s main products include TYRA-300, an oral selective FGFR3 inhibitor in Phase 2 development for treating FGFR3-positive solid tumors such as metastatic urothelial carcinoma and pediatric achondroplasia, TYRA-200, an oral FGFR1/2/3 inhibitor in clinical trials for FGFR2-driven intrahepatic cholangiocarcinoma and other advanced solid tumors, and TYRA-430, an oral FGFR4/3-biased inhibitor targeting FGF19+/FGFR4-driven cancers in ongoing clinical trials. Recent major developments include clearance by the U.S. FDA to proceed with a Phase 2 clinical trial of TYRA-300 for pediatric achondroplasia (BEACH301), coupled with positive interim clinical proof-of-concept results for TYRA-300 in metastatic urothelial carcinoma from the SURF301 study. The company is advancing multiple Phase 2 studies for TYRA-300, including SURF302 for intermediate-risk non-muscle invasive bladder cancer and BEACH301 for achondroplasia, alongside ongoing SURF201 Phase 1 studies for TYRA-200 and SURF431 for TYRA-430. Tyra Biosciences also completed a $200 million private placement financing in early 2024 to bolster its pipeline development and clinical trial progression. The company maintains a robust clinical pipeline with a focus on targeting resistance mechanisms in oncology and genetically defined conditions, supported by strategic investor backing from firms including RA Capital Management and Boxer Capital. Tyra operates primarily within the biotechnology industry’s precision oncology segment with a focus on large markets including oncology and rare genetic diseases. Its targeted therapy candidates are designed to address FGFR-driven cancers and skeletal dysplasia conditions. The company conducts its clinical and preclinical operations across the United States with a focus on advancing molecularly targeted therapies that improve patient outcomes through precision medicine. Tyra Biosciences remains publicly traded on the NASDAQ under the ticker symbol TYRA and continues to extend its clinical-stage footprint through systematic clinical trial progression and strategic capital raises.
Company News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA
Here's Why Tyra Biosciences (TYRA) is Poised for a Turnaround After Losing 27% in 4 Weeks
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA
Tyra Biosciences, Inc. (NASDAQ:TYRA) Stock Has Consensus Target Price of $46.89
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA
Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA
Tyra Biosciences, Inc. (TYRA) Discusses Initial SURF302 Results on Oral Dabogratinib for Intermediate Risk NMIBC Transcript
Why Is Tyra Biosciences Stock Sinking Wednesday?
Tyra Plummets To 10-Month Low On Mixed Bladder Cancer Results
Tyra Biosciences Stock Plunges 22% as Bladder Cancer Pill Fails to Impress
Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with Dabogratinib
Tyra Biosciences to Present at the Cantor Global Healthcare Conference
Tyra Biosciences: 'Hold' IR-NMIBC Data September 9th 2026, With Caution Ahead For 2027 Readouts